Harnessing the Power of ROR1
Location: United States, California, San Diego
Employees: 11-50
Total raised: $195M
Founded date: 2017
Investors 7
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.07.2020 | Series B | $137M | - |
| 01.10.2018 | Series A | $58M | - |
Mentions in press and media 18
| Date | Title | Description |
| 06.11.2020 | Merck to Acquire VelosBio, for $2.75 Billion | Merck (NYSE: MRK), known as MSD outside the United States and Canada, is through a subsidiary, is to acquire VelosBio Inc., a San Diego CA-based clinical-stage biopharmaceutical company, for $2.75 billion. The closing of the transaction, wh... |
| 09.07.2020 | VelosBio Raises $137M in Series B | SAN DIEGO, CA, VelosBio announced the completion of an oversubscribed Series B financing of $137 million led by Matrix Capital Management. >> Click here for more funding data on VelosBio >> To export VelosBio funding data to... |
| 08.07.2020 | VelosBio raises $137M Series B round to support suite of ROR1-targeting cancer drugs | The company said it plans to use the money to support clinical development of its lead drug candidate, VLS-101. The drug is an antibody-drug conjugate that targets ROR1 and is currently in a Phase I trial of 210 patients with various blood ... |
| 08.07.2020 | VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology | - |
| 08.07.2020 | VelosBio Finds $137M For Oncology Efforts | San Diego-based biopharmaceuticals developer VelosBio says it has raised $137M in a Series B funding roudn, to go towards its oncology efforts. The funding was led by Matrix Capital and Surveyor Capital, and also included Adage Capital Mana... |
| 08.07.2020 | VelosBio closes $137m Series B | - |
| 08.07.2020 | VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology | - |
| 08.07.2020 | ARIX BIOSCIENCE PLC Arix Bioscience Plc : - VelosBio completes $137 million Series B financing | Arix Bioscience plc VelosBio completes $137 million Series B financing LONDON, 8 July 2020: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today... |
| 08.07.2020 | VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology | VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the completion of an ove... |
| 08.07.2020 | VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology | - |
Show more